[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Kiran et al., 2023 - Google Patents

Design and development of benzyl piperazine linked 5-phenyl-1, 2, 4-triazole-3-thione conjugates as potential agents to combat Alzheimer's disease

Kiran et al., 2023

Document ID
7438649407945817255
Author
Kiran P
Waiker D
Verma A
Saraf P
Bhardwaj B
Kumar H
Singh A
Kumar P
Singh N
Srikrishna S
Trigun S
Shrivastava S
Publication year
Publication venue
Bioorganic Chemistry

External Links

Snippet

Our present work demonstrates the molecular hybridization-assisted design, synthesis, and biological evaluation of 22 benzylpiperazine-linked 1, 2, 4-triazole compounds (PD1-22) as AD modifying agents. All the compounds were tested for their in vitro hChEs, hBACE-1, and …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings

Similar Documents

Publication Publication Date Title
Tripathi et al. Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1, 3, 4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease
AlFadly et al. Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase
Kumar et al. Advancements in the development of multi-target directed ligands for the treatment of Alzheimer’s disease
González et al. Developments with multi-target drugs for Alzheimer’s disease: An overview of the current discovery approaches
Kiran et al. Design and development of benzyl piperazine linked 5-phenyl-1, 2, 4-triazole-3-thione conjugates as potential agents to combat Alzheimer’s disease
Simões-Pires et al. HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?
Gutti et al. Development of pyrazole and spiropyrazoline analogs as multifunctional agents for treatment of Alzheimer’s disease
Mandal et al. Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation
Riazimontazer et al. Design, synthesis and biological activity of novel tacrine-isatin Schiff base hybrid derivatives
Liao et al. Synthesis and biological evaluation of 1, 2, 4-triazole derivatives as potential neuroprotectant against ischemic brain injury
Abd-Elrahman et al. mGluR5 contribution to neuropathology in Alzheimer mice is disease stage-dependent
Erdogan et al. Design, synthesis and biological evaluation of new benzoxazolone/benzothiazolone derivatives as multi-target agents against Alzheimer’s disease
Malhotra et al. Pharmacological relevance of CDK inhibitors in Alzheimer's disease
Choubey et al. Design, synthesis, and evaluation of N-benzylpyrrolidine and 1, 3, 4-oxadiazole as multitargeted hybrids for the treatment of Alzheimer’s disease
Mozaffarnia et al. Design, synthesis and biological evaluation of 2, 3-dihydro-5, 6-dimethoxy-1H-inden-1-one and piperazinium salt hybrid derivatives as hAChE and hBuChE enzyme inhibitors
Patel et al. Novel multitarget directed triazinoindole derivatives as anti-Alzheimer agents
Basha et al. New flavone-cyanoacetamide hybrids with a combination of cholinergic, antioxidant, modulation of β-amyloid aggregation, and neuroprotection properties as innovative multifunctional therapeutic candidates for Alzheimer’s disease and unraveling their mechanism of action with acetylcholinesterase
Yurttaş et al. Synthesis and biological evaluation of some 1, 2‐disubstituted benzimidazole derivatives as new potential anticancer agents
Waiker et al. Design, synthesis, and biological evaluation of piperazine and N-benzylpiperidine hybrids of 5-phenyl-1, 3, 4-oxadiazol-2-thiol as potential multitargeted ligands for alzheimer’s disease therapy
Mishra et al. Development of novel carbazole derivatives with effective multifunctional action against Alzheimer’s diseases: design, synthesis, in silico, in vitro and in vivo investigation
Jiang et al. Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer’s disease
Islam et al. Synthesis, molecular docking and enzyme inhibitory approaches of some new chalcones engrafted pyrazole as potential antialzheimer, antidiabetic and antioxidant agents
Avram et al. Potential therapeutic approaches to Alzheimer’s disease by bioinformatics, cheminformatics and predicted Adme-Tox tools
Manzoor et al. Dual targeting of acetylcholinesterase and tau aggregation: Design, synthesis and evaluation of multifunctional deoxyvasicinone analogues for Alzheimer’s disease
Waiker et al. Development and Evaluation of Some Molecular Hybrids of N-(1-Benzylpiperidin-4-yl)-2-((5-phenyl-1, 3, 4-oxadiazol-2-yl) thio) as Multifunctional Agents to Combat Alzheimer’s Disease